Zanamivir, a potent neuraminidase inhibitor, remains a frontline defense in the global management of influenza. Marketed under the brand name Relenza, its role extends from seasonal outbreak control to national pandemic stockpiles. Following heightened global health awareness, the market is experiencing a strategic reassessment, projected to grow from USD 342.4 million in 2024 to USD 484.8...